Načítá se...
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
AIMS: The aim of our study was to investigate heterogeneity of health status treatment response of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF). METHODS AND RESULTS: We leveraged data from CHAMP‐HF, an observational registry of 140 US clinics and 5026 ou...
Uloženo v:
| Vydáno v: | ESC Heart Fail |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7835503/ https://ncbi.nlm.nih.gov/pubmed/33170559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12981 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|